Celgenyx Completes RMB 100M Series A Financing for Next-Gen Cell Therapy Development
China-based Hangzhou Celgenyx Gene Technology Co., Ltd has announced the completion of a Series A...
Company
Easy-Flow Medical Secures Angel Funding for Peripheral Device Development
China-based peripheral interventional device manufacturer Shanghai Easy-Flow Medical Tech Co., Ltd has reportedly raised “tens...
Hengrui Medicine Gains Approval for Phase Ib/II Study of SHR-A1811 and SHR-1701 in HER2-Positive Gastric Cancer
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval to initiate a...
Zhejiang Pushkang Biotech Raises RMB 100M in Series C+ Financing
China-based Zhejiang Pushkang Biotechnology Co., Ltd, a leading centrifugal microfluidic platform company, has reportedly raised...
Sinovac Partners with Colombia University to Boost Vaccine R&D
China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA)...
SeeNeuro Medical Raises RMB 100M in Series B Funding for Neural Regulation Devices
Hangzhou-based SeeNeuro Medical, a developer of implantable neural regulation devices, has reportedly raised RMB 100...
MicuRx Pharmaceuticals Concludes US Phase I Study for MRX-8
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the conclusion of Phase I...
Henlius Biotech’s Hanbeitai Approved for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving a fourth indication approval from the...
Antengene’s Xpovio Receives Taiwan FDA Approval for Multiple Indications
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan...
AIM Vaccine Receives CDE Approval for Serum-Free Rabies Vaccine Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the...
Rici Healthcare to Acquire Unicorn II Holdings for RMB 180M
China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to...
Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing...
Ambrx Biopharma Halts Development of HER2 ADC ARX788, Cuts Workforce
US-based, China-owned biotech Ambrx Biopharma Inc. (NYSE: AMAM) has announced plans to end the development...
CATUG Biotechnology Partners with Duoning to Advance mRNA Industrialization
China-based CATUG Biotechnology (Suzhou) Co., Ltd has entered into a partnership with compatriot firm Shanghai...
Betta Pharmaceuticals’ BPI-460372 Accepted for Clinical Trial Review by NMPA
China’s Betta Pharmaceuticals (SHE: 300558) has announced that its clinical trial filing for the Category...
Frontier Biotechnologies Secures Approval for HIV Therapy Alfusid
Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...
Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China
The Center for Drug Evaluation (CDE) website indicates that China-based Jiangsu Hengrui Medicine Co., Ltd’s...
China Approves GSK’s Juluca for HIV-1 Infection
The National Medical Products Administration (NMPA) has approved the market application for GlaxoSmithKline’s (GSK, NYSE:...
Hengrui Medicine Files for Dalpiciclib as Initial Therapy for Breast Cancer
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...
HitGen Partners with C4X Discovery to Identify Novel Inflammatory Disease Treatments
China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc...